Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 3

Completed

Conditions: Lung Cancer
Radiation Toxicity

Interventions: Biological: Cetuximab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: 60 Gy RT
Radiation: 74 Gy RT

First Posted Date: 2007-09-24

Last Posted Date: 2022-06-21

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 544

Registration Number: NCT00533949

Locations: 🇺🇸
Shore Regional Cancer Center at Memorial Hospital - Easton, Easton, Maryland, United States
🇺🇸
CCOP - Christiana Care Health Services, Newark, Delaware, United States
🇺🇸
Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States

and more 210 locations

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: BAY 43-9006
Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2007-09-21

Last Posted Date: 2016-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00533585

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: enzastaurin
Drug: carboplatin
Drug: pemetrexed
Drug: bevacizumab
Drug: Placebo

First Posted Date: 2007-09-21

Last Posted Date: 2021-05-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT00533429

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States

Triple Negative Breast Cancer Trial

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel

First Posted Date: 2007-09-20

Last Posted Date: 2019-02-20

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 400

Registration Number: NCT00532727

Locations: 🇬🇧
Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Azacitidine
Drug: Valproic Acid
Drug: Carboplatin

First Posted Date: 2007-09-14

Last Posted Date: 2013-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00529022

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: SGN-40
Drug: placebo
Drug: rituximab
Drug: etoposide
Drug: carboplatin
Drug: ifosfamide

First Posted Date: 2007-09-14

Last Posted Date: 2015-02-25

Lead Sponsor: Seagen Inc.

Target Recruit Count: 151

Registration Number: NCT00529503

Locations: 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇦🇺
St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia

and more 63 locations

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Phase 2

Completed

Conditions: Lung Cancer
Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Ipilimumab
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-09-11

Last Posted Date: 2018-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 334

Registration Number: NCT00527735

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States
🇺🇦
Local Institution, Uzhgorod, Ukraine

and more 22 locations

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Not Applicable

Conditions: Neuroblastoma

First Posted Date: 2007-09-10

Last Posted Date: 2015-07-16

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 360

Registration Number: NCT00526318

Locations: 🇩🇪
Klinikum Augsburg, Augsburg, Germany
🇩🇪
Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
🇩🇪
Klinikum Duisburg, Duisburg, Germany

and more 64 locations

Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Dietary Supplement: selenomethionine
Drug: carboplatin
Drug: paclitaxel
Other: laboratory biomarker analysis
Radiation: radiation therapy

First Posted Date: 2007-09-10

Last Posted Date: 2017-11-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00526890

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3

Terminated

Conditions: Recurrent Breast Carcinoma
Stage IV Breast Cancer
Breast Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel
Other: Placebo
Biological: Trastuzumab

First Posted Date: 2007-08-27

Last Posted Date: 2017-02-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT00520975

Locations: 🇺🇸
Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸
Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States
🇺🇸
Wayne Hospital, Greenville, Ohio, United States

and more 370 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy